Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.4.2.8 (hypoxanthine-guanine phosphoribosyltransferase)
 2,527 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have produced somatic cell hybrids between mouse plasocytoma cells deficient in hypoxanthine phosphoribosyltransferase (P3 x 63 Ag8) and spleen cells derived from mice immunized with purified human plasma fibronectin. We report herein the properties of monoclonal anti-fibronectin antibodies released by eight different clones.
 ...
PMID:Somatic cell hybrids producing antibodies specific to human fibronectin. 615 31

Thirty segregant clones were back-selected in 8AG or 5BUdR media from a non-tumorigenic human intraspecific hybrid line (HeLa TK- X fibroblasts HPRT-) displaying a high plasminogen activator (PA) level, a disorganized fibronectin (FN) matrix and anchorage-independence. These clones exhibited a widely modulated expression of the above markers concomitantly with different degrees of chromosome loss. Out of six representative segregant clones tested in nude mice, two were found to re-express tumorigenicity. No significant correlation was observed between PA or FN levels and anchorage-independence, as well as between these markers and tumorigenicity.
 ...
PMID:Studies on transformation markers and tumorigenicity in segregant clones from a human hybrid line. 668 60

Using a monoclonal antibody specific for human fibronectin (FN), we screened hybrid clones derived from the fusion of FN+ human fibroblasts, carrying a 11/X translocation, and FN-, HPRT- mouse cells for the production of this glycoprotein. Since no hybrid clone retaining the human der 11 chromosome was found to produce any human fibronectin, the segment of chromosome 11 included in the rearranged chromosome (11qter leads to 11p13) probably does not carry the structural locus for fibronectin.
 ...
PMID:Human fibroblasts X mouse cell hybrids, containing a human 11/X translocation, do not express human fibronectin. 685 Aug 63

To isolate and characterize effector molecules of the transforming growth factor beta (TGFbeta) signaling pathway we have used a genetic approach involving the generation of stable recessive mutants, defective in their TGFbeta signaling, which can subsequently be functionally complemented to clone the affected genes. We have generated a cell line derived from a hypoxanthine-guanine phosphoribosyltransferase negative (HPRT-) HT1080 clone that contains the selectable marker Escherichia coli guanine phosphoribosyltransferase (gpt) linked to a TGFbeta-responsive promoter. This cell line proliferates or dies in the appropriate selection medium in response to TGFbeta. We have isolated three distinct TGFbeta-unresponsive mutants following chemical mutagenesis. Somatic cell hybrids between pairs of individual TGFbeta-unresponsive clones reveal that each is in a distinct complementation group. Each mutant clone retains all three TGFbeta receptors yet fails to induce a TGFbeta-inducible luciferase reporter construct or TGFbeta-mediated plasminogen activator inhibitor-1 (PAI-1) expression. Two of the three have an attenuated TGFbeta-induced fibronectin response, whereas in the other mutant the fibronectin response is intact. These TGFbeta-unresponsive cells should allow selection and identification of signaling molecules through functional complementation.
 ...
PMID:Isolation and characterization of mutant cell lines defective in transforming growth factor beta signaling. 875 31